… and CAD commencing warfarin, dabigatran, or rivaroxaban. … versus warfarin, while low-dose
NOACs reduced safety risks … this study did not include apixaban, prior analysis of patients …

… rates of major bleeding (MB) in patients with atrial fibrillation. … comparing apixaban to
dabigatran, rivaroxaban, or warfarin. … both standard-dose and low-dose apixaban, with a …

… patients in this NMA received low-dose dabigatran (110 mg), … apixaban, dabigatran, and
rivaroxaban were more effective than warfarin on reducing the risks of stroke and haemorrhage; …

… in the present study because the expenses of apixaban and … -dose dabigatran, and those
on low-dose rivaroxaban had a … safety of dabigatran versus warfarin for GI bleeding, distinct …

… for Asian patients with non-valvular atrial fibrillation. We aimed … Low-dose NOACs were
defined as dabigatran 110 mg bid, … together even though rivaroxaban, apixaban, and edoxaban …

… : “dabigatran OR apixaban OR rivaroxaban OR warfarin OR direct oral anticoagulant OR
DOAC” AND “non-valvular atrial fibrillation OR atrial fibrillation” … prescribed a “low-dose” DOAC. …

… outcomes in low-dose NOACs (dabigatran, rivaroxaban, and … Xa inhibitors OR dabigatran
OR rivaroxaban OR apixaban OR … with decreased risks of thromboembolic and bleeding events…

… record of DOACs (apixaban, rivaroxaban, or edoxaban) at least … Bleeding risk of apixaban,
dabigatran, and low-dose … with non-valvular atrial fibrillation: a propensity matched analysis …

… We compared stroke, bleeding, and mortality rates on and off therapy for standard and
low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort. We …

… for the management of patients with atrial fibrillation: Executive sum… Bleeding risk of apixaban,
dabigatran, and low-dose rivar… with warfarin in Japanese patients with nonvalvular atrial …